Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
7.61 USD | -0.13% | -7.20% | -13.23% |
Mar. 27 | MiMedx Group Says FDA Affirms Axiofill Falls Short of Regulatory Standards for Tissue-Based Products | MT |
Mar. 27 | MiMedx Says FDA Still Won't Budge on Axiofill Designation, Files Lawsuit | DJ |
Financials (USD)
Sales 2024 * | 357M | Sales 2025 * | 403M | Capitalization | 1.12B |
---|---|---|---|---|---|
Net income 2024 * | 43M | Net income 2025 * | 56M | EV / Sales 2024 * | 3.13 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 2.77 x |
P/E ratio 2024 * |
24.7
x | P/E ratio 2025 * |
19.5
x | Employees | 895 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 96.1% |
Latest transcript on MiMedx Group, Inc.
1 day | -0.13% | ||
1 week | -7.20% | ||
Current month | -6.74% | ||
1 month | -9.40% | ||
3 months | -15.44% | ||
6 months | -1.81% | ||
Current year | -13.23% |
Managers | Title | Age | Since |
---|---|---|---|
Joe Capper
CEO | Chief Executive Officer | 60 | 23-01-26 |
Douglas Rice
DFI | Director of Finance/CFO | 58 | 23-07-04 |
John R. Harper
CTO | Chief Tech/Sci/R&D Officer | - | 21-05-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
William Hawkins
BRD | Director/Board Member | 70 | 20-07-01 |
Phyllis Gardner
BRD | Director/Board Member | 73 | 21-03-07 |
K. Newton
BRD | Director/Board Member | 61 | 19-06-18 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.05% | 2 M€ | -.--% | ||
0.01% | 735 M€ | -.--% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-03-27 | 7.61 | -0.13% | 1,821,742 |
24-03-26 | 7.62 | -2.68% | 739,261 |
24-03-25 | 7.83 | -2.61% | 746,715 |
24-03-22 | 8.04 | -1.47% | 576,860 |
24-03-21 | 8.16 | -0.49% | 799,196 |
Delayed Quote Nasdaq, March 27, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-13.23% | 1.12B | |
+9.23% | 1.07B | |
-8.41% | 150M | |
+13.27% | 62.25M | |
-18.15% | 59.9M | |
+2.98% | 59.62M |